8-K
filed January 21, 2026, 6:59 PM ET
ticker AEON
CIK 0001837607
other material
confidence high
sentiment positive
materiality 0.70
AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA
AEON Biopharma, Inc.
- Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
- Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.
- Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.
- AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.
- Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued 11,918,380 newly issued shares of Common Stock of common stock to Daewoong Pharmaceutical Co., LTD..
- Security
- common stock
- Shares
- 11,918,380 newly issued shares of Common Stock
- Purchaser
- Daewoong Pharmaceutical Co., LTD.
Exact text from the filing
on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share of warrant to Daewoong Pharmaceutical Co., LTD..
- Security
- warrant
- Shares
- warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share
- Purchaser
- Daewoong Pharmaceutical Co., LTD.
Exact text from the filing
(iii) warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceutical Co., LTD..
- Security
- convertible note
- Shares
- $1,500,000
- Purchaser
- Daewoong Pharmaceutical Co., LTD.
Exact text from the filing
(ii) a new senior secured convertible note in a principal amount of $1,500,000 (the “New Note”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
AEON Biopharma, Inc. issued 11,236,631 pre-funded warrants to purchase shares of Common Stock of warrant to Daewoong Pharmaceutical Co., LTD..
- Security
- warrant
- Shares
- 11,236,631 pre-funded warrants to purchase shares of Common Stock
- Purchaser
- Daewoong Pharmaceutical Co., LTD.
Exact text from the filing
on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.